RxDoctor Payments DataLook up a doctor →

Glen Biddulph, MD

Internal Medicine · Layton, UTNPI 1518999275

Payments from drug & device makers

$33,616in general payments, 2019–2025

Across 902 payments — averaging $37.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$21K
  • AbbVie$3K
  • Novo Nordisk$1K
  • Lilly USA, LLC$681
  • Amgen$652
  • Novartis$586
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer2$20,696
AbbVie(2 entities)196$2,813
Novo Nordisk114$1,177
Lilly USA, LLC52$681
Amgen46$652
Novartis38$586
Pfizer42$519
Astellas Pharma US Inc31$517
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC49$490
Nestle Healthcare Nutrition Inc.24$416
GSK21$323
AstraZeneca14$277
Johnson & Johnson(2 entities)16$250
Boehringer Ingelheim13$248
Otsuka America Pharmaceutical, Inc.14$236
Sanofi-aventis U.S. LLC16$234
Corium, LLC10$204
Axsome Therapeutics, Inc.11$199
Takeda Pharmaceuticals U.S.A., Inc.12$172
Amarin Pharma, Inc.11$172
E.r. Squibb & Sons, L.L.C.11$166
Daiichi Sankyo Inc.8$157
Aimmune Therapeutics, Inc.8$152
Antares Pharma, Inc.6$110
Biogen7$109
Lundbeck LLC5$108
Exact Sciences6$104
Avanir Pharmaceuticals, Inc.7$101
Teva Pharmaceuticals USA, Inc.6$91
Sumitomo Pharma America, Inc.7$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$85
Idorsia Pharmaceuticals US Inc5$77
Merck6$77
Boston Scientific6$76
Halozyme Inc4$72
Dexcom, Inc.5$70
Biohaven Pharmaceutical Holding Company Ltd.4$64
Jazz Pharmaceuticals Inc.4$62
Alkermes, Inc.4$59
Abbott3$57
Bausch Health US, LLC4$55
Kowa Pharmaceuticals America, Inc.2$47
Acadia Pharmaceuticals Inc3$41
Lifescan, Inc.2$41
Neurocrine Biosciences, Inc.2$40
Sunovion Pharmaceuticals Inc.3$39
Scilex Pharmaceuticals Inc.3$39
Redhill Biopharma Inc.2$34
Grifols USA, LLC2$34
Biohaven Pharmaceuticals, Inc.2$33
Phathom Pharmaceuticals, Inc.2$33
Harmony Biosciences LLC2$32
Ardelyx, Inc.2$31
Lucid Diagnostics Inc.2$29
Shield Therapeutics Inc1$29
Mannkind Corporation2$28
Edwards Lifesciences1$26
ANI Pharmaceuticals, Inc.1$26
Bard Peripheral Vascular, Inc.1$21
Ultragenyx Pharmaceutical Inc.1$19

How this compares

$33,616 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$324,290
Medicare patients
472
Services billed
25,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Layton

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →